US Physical Therapy/$USPH
1D1W1MYTD1Y5YMAX
Capital at risk
About US Physical Therapy
US Physical Therapy Inc through its subsidiaries operate outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
- Ticker
- $USPH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,374
- Headquarters
- Houston, United States
- Website
- www.usph.com
USPH Metrics
BasicAdvanced
$1.2B
458.65
$0.18
1.13
$1.83
2.29%
Price and volume
Market cap
$1.2B
Beta
1.13
52-week high
$93.50
52-week low
$58.19
Average daily volume
185K
Dividend rate
$1.83
Financial strength
Current ratio
1.271
Quick ratio
1.132
Long term debt to equity
0.441
Total debt to equity
0.503
Dividend payout ratio (TTM)
85.50%
Interest coverage (TTM)
7.40%
Profitability
EBITDA (TTM)
102.009
Gross margin (TTM)
21.47%
Net profit margin (TTM)
4.01%
Operating margin (TTM)
9.90%
Effective tax rate (TTM)
26.06%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
4.10%
Return on equity (TTM)
6.51%
Valuation
Price to earnings (TTM)
458.647
Price to revenue (TTM)
1.517
Price to book
2.68
Price to tangible book (TTM)
-2.7
Price to free cash flow (TTM)
19.041
Free cash flow yield (TTM)
5.25%
Free cash flow per share (TTM)
4.229
Dividend yield (TTM)
2.27%
Forward dividend yield
2.29%
Growth
Revenue change (TTM)
11.36%
Earnings per share change (TTM)
-92.32%
3-year revenue growth (CAGR)
11.83%
10-year revenue growth (CAGR)
8.87%
3-year earnings per share growth (CAGR)
-55.03%
10-year earnings per share growth (CAGR)
-20.22%
3-year dividend per share growth (CAGR)
2.70%
10-year dividend per share growth (CAGR)
11.02%
What the Analysts think about USPH
Analyst ratings (Buy, Hold, Sell) for US Physical Therapy stock.
Analyst projections of the future price of US Physical Therapy stock.
Bulls say / Bears say
USPH generated net revenue of $214.06 million in Q2 2026, an 8.5% year-over-year increase that exceeded consensus estimates of $211.36 million (MarketBeat)
The company completed a 12-clinic acquisition for $16.4 million in July 2026 and has three announced 2026 acquisitions totaling $38 million, bolstering its market footprint (MarketBeat)
In February 2026, US Physical Therapy entered a 10-year strategic alliance with a prominent New York hospital system to integrate 60 clinics into its network, enhancing referral channels and market penetration (USPH Press Release)
USPH reported a GAAP EPS of $0.75 for Q2 2026, missing analysts’ consensus by $0.06 and underscoring earnings pressure (MarketBeat)
Adjusted EBIT margin for Q2 2026 declined to 8.0% from 8.9% in Q2 2025, reflecting margin compression amid rising operating costs (USPH Earnings Presentation)
Management highlighted ongoing Medicare reimbursement headwinds in its April 16, 2026 shareholder letter, noting five years of rate pressure that may constrain net revenue per visit (SEC 10-K)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
USPH Financial Performance
Revenues and expenses
USPH Earnings Performance
Company profitability
Upcoming events
No upcoming events
USPH News
AllArticlesVideos
Funds containing USPH
AllUSDGBPEUR
Fund name | Fund size | $USPH weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.